Constitutive CHK1 Expression Drives a pSTAT3-CIP2A Circuit that Promotes Glioblastoma Cell Survival and Growth.


Journal

Molecular cancer research : MCR
ISSN: 1557-3125
Titre abrégé: Mol Cancer Res
Pays: United States
ID NLM: 101150042

Informations de publication

Date de publication:
05 2020
Historique:
received: 16 09 2019
revised: 14 01 2020
accepted: 17 02 2020
pubmed: 23 2 2020
medline: 6 3 2021
entrez: 22 2 2020
Statut: ppublish

Résumé

High-constitutive activity of the DNA damage response protein checkpoint kinase 1 (CHK1) has been shown in glioblastoma (GBM) cell lines and in tissue sections. However, whether constitutive activation and overexpression of CHK1 in GBM plays a functional role in tumorigenesis or has prognostic significance is not known. We interrogated multiple glioma patient cohorts for expression levels of CHK1 and the oncogene cancerous inhibitor of protein phosphatase 2A (CIP2A), a known target of high-CHK1 activity, and examined the relationship between these two proteins in GBM. Expression levels of CHK1 and CIP2A were independent predictors for reduced overall survival across multiple glioma patient cohorts. Using siRNA and pharmacologic inhibitors we evaluated the impact of their depletion using both

Identifiants

pubmed: 32079743
pii: 1541-7786.MCR-19-0934
doi: 10.1158/1541-7786.MCR-19-0934
doi:

Substances chimiques

Autoantigens 0
Biomarkers, Tumor 0
CIP2A protein, human 0
Intracellular Signaling Peptides and Proteins 0
Membrane Proteins 0
STAT3 Transcription Factor 0
STAT3 protein, human 0
CHEK1 protein, human EC 2.7.11.1
Checkpoint Kinase 1 EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

709-722

Informations de copyright

©2020 American Association for Cancer Research.

Auteurs

Anchit Khanna (A)

Adult Cancer Program, Lowy Cancer Research Centre, University of New South Wales Sydney, New South Wales, Australia. jpimanda@unsw.edu.au a.khanna@unsw.edu.au.
Prince of Wales Clinical School, University of New South Wales Sydney, New South Wales, Australia.

Julie A I Thoms (JAI)

Adult Cancer Program, Lowy Cancer Research Centre, University of New South Wales Sydney, New South Wales, Australia.
School of Medical Sciences, University of New South Wales Sydney, New South Wales, Australia.

Brett W Stringer (BW)

QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

Sylvia A Chung (SA)

Adult Cancer Program, Lowy Cancer Research Centre, University of New South Wales Sydney, New South Wales, Australia.
Prince of Wales Clinical School, University of New South Wales Sydney, New South Wales, Australia.

Kathleen S Ensbey (KS)

QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

Toni Rose Jue (TR)

Adult Cancer Program, Lowy Cancer Research Centre, University of New South Wales Sydney, New South Wales, Australia.
Prince of Wales Clinical School, University of New South Wales Sydney, New South Wales, Australia.

Zeenat Jahan (Z)

Adult Cancer Program, Lowy Cancer Research Centre, University of New South Wales Sydney, New South Wales, Australia.

Shruthi Subramanian (S)

Adult Cancer Program, Lowy Cancer Research Centre, University of New South Wales Sydney, New South Wales, Australia.
Prince of Wales Clinical School, University of New South Wales Sydney, New South Wales, Australia.

Govardhan Anande (G)

Adult Cancer Program, Lowy Cancer Research Centre, University of New South Wales Sydney, New South Wales, Australia.
Prince of Wales Clinical School, University of New South Wales Sydney, New South Wales, Australia.

Han Shen (H)

Adult Cancer Program, Lowy Cancer Research Centre, University of New South Wales Sydney, New South Wales, Australia.
Prince of Wales Clinical School, University of New South Wales Sydney, New South Wales, Australia.
Centre for Cancer Research, Westmead Institute for Medical Research, Westmead, Australia.
Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Camperdown, Australia.

Ashwin Unnikrishnan (A)

Adult Cancer Program, Lowy Cancer Research Centre, University of New South Wales Sydney, New South Wales, Australia.
Prince of Wales Clinical School, University of New South Wales Sydney, New South Wales, Australia.

Kerrie L McDonald (KL)

Adult Cancer Program, Lowy Cancer Research Centre, University of New South Wales Sydney, New South Wales, Australia.
Prince of Wales Clinical School, University of New South Wales Sydney, New South Wales, Australia.

Bryan W Day (BW)

QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

John E Pimanda (JE)

Adult Cancer Program, Lowy Cancer Research Centre, University of New South Wales Sydney, New South Wales, Australia. jpimanda@unsw.edu.au a.khanna@unsw.edu.au.
Prince of Wales Clinical School, University of New South Wales Sydney, New South Wales, Australia.
School of Medical Sciences, University of New South Wales Sydney, New South Wales, Australia.
Department of Haematology, Prince of Wales Hospital, Randwick, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH